Indeed, biomarker-driven approaches may help to identify patients likely to benefit from ICOS agonist or antagonistic therapies and suggest that ICOS agonists may be more effective in tumors with low Treg presence or when combined with treatments that deplete tumor-infiltrating Tregs [68]. Here, ICOS is linked to neoplasm.